Fenwick Represents Curi Bio in $10M Series B Funding

Fenwick represented Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, in its $10 million Series B funding. The round was led by DreamCIS.

Curi Bio will use the funds to scale its integrated platforms, accelerate the development of new platforms, and expand its commercial reach across the globe. More information can be obtained here.

The Fenwick transaction team was led by corporate partners Andy Albertson and Kat Duncan and included associates Olga Terets and Raffi Terteryan.